Axsome Announces Availability of 1st and Only Oral NMDA Receptor Antagonist for Major Depressive Disorder

 AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week^1-4

Auvelity On My Side offers comprehensive patient support services including access and prescription drug support    

Axsome Therapeutics Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that AUVELITY™ (dextromethorphan HBr-bupropion HCl) is now available by prescription in the United States for the treatment of major depressive disorder (MDD) in adults.¹ AUVELITY is the first and only oral N-methyl D-aspartate (NMDA) receptor antagonist approved for the treatment of MDD, and the first and only rapid-acting oral medicine approved for the treatment of MDD with labeling of statistically significant antidepressant efficacy compared to placebo starting at one week.^1-4 AUVELITY was developed with FDA Breakthrough Therapy designation for the treatment of MDD.

https://www.biospace.com/article/releases/axsome-therapeutics-announces-availability-of-auvelity-the-first-and-only-oral-nmda-receptor-antagonist-for-the-treatment-of-major-depressive-disorder-in-adults/